Skip to main content
诺思兰德 logo

诺思兰德 — Investor Relations & Filings

Ticker · 920047 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 539 across all filing types
Latest filing 2026-04-22 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920047

About 诺思兰德

https://www.northland-bio.com/

Northland Biotech focuses on the research, development, and commercialization of gene therapies and recombinant protein pharmaceuticals. The company’s primary therapeutic areas include cardiovascular diseases, peripheral arterial diseases, and ophthalmology. Its core R&D pipeline features NL003, a hepatocyte growth factor gene therapy targeting critical limb ischemia, and NL005, a recombinant human thymosin beta 4 for treating myocardial ischemia. Beyond its innovative pipeline, the company maintains advanced manufacturing facilities for biologics and ophthalmic preparations, producing a range of specialized eye drops. By leveraging its proprietary technology platforms, Northland Biotech aims to provide effective treatments for chronic and degenerative conditions through advanced molecular medicine.

Recent filings

Filing Released Lang Actions
关于终止部分研发项目的公告
Regulatory Filings Classification · 90% confidence The document is a corporate announcement by Beijing 诺思兰德生物技术股份有限公司 regarding the termination of certain R&D projects (“关于终止部分研发项目的公告”). It is not an earnings release, financial report, board change, merger, share issuance, or any specifically defined category but rather a general business update disclosed via the stock exchange. Therefore, it falls under the fallback category of general regulatory announcements (Regulatory Filings).
2026-04-22 Chinese
中泰证券股份有限公司关于北京诺思兰德生物技术股份有限公司使用部分闲置募集资金进行现金管理的核查意见
Capital/Financing Update Classification · 72% confidence The document is a formal third-party (sponsor) review opinion on the use of idle proceeds from a prior equity financing. It is not an earnings release, management commentary, or annual/interim report, nor is it a simple publication notice. Instead, it updates investors and regulators on the company’s financing activity—specifically, the use of raised funds for cash management. Therefore, it best fits under the “Capital/Financing Update” category.
2026-04-22 Chinese
独立董事候选人声明与承诺（刘荣耀）
Board/Management Information Classification · 85% confidence The document is a formal public announcement by Beijing Nordland Biotechnology Co., Ltd. regarding the nomination of Liu Rongyao as an independent director candidate, including detailed qualifications, independence declarations, and commitments. This is clearly related to the company’s board composition and management structure rather than financial results, ESG reporting, or regulatory disclosures of other types. It is not simply a notification of a report’s publication, nor a voting result or proxy statement, but is announcing a board-level nomination. Therefore, it falls under Board/Management Information (MANG).
2026-04-22 Chinese
2025年度独立董事述职报告（任自力）
Governance Information Classification · 75% confidence The document is the 2025 annual work report by an independent director of Beijing Nordland Biotechnology Co., Ltd., detailing duties performed, meetings attended, governance oversight, and compliance with China’s independent director rules. It is not an earnings release, proxy, or capital change notice, nor a full annual or interim financial report. Rather, it is a governance disclosure on board structure and director responsibilities, fitting the “Governance Information” category.
2026-04-22 Chinese
2025年度独立董事述职报告（王英典）
Governance Information Classification · 85% confidence The document is a 2025 independent director’s annual performance report submitted by Wang Yingdian of Beijing Northland Biotech Co., Ltd. It is not an earnings announcement, financial report, or change in management, but a governance-related disclosure detailing the independent director’s duties, meetings attended, and governance oversight. This aligns with our definition of Governance Information (CGR).
2026-04-22 Chinese
董事换届公告
Board/Management Information Classification · 97% confidence The document is titled “董事换届公告” (Board Re-election Announcement) and details the nomination of new directors, their shareholdings, terms, compliance statements, independent director opinions, and outgoing board members. It is clearly an announcement of changes in the company’s board of directors, matching the Board/Management Information category.
2026-04-22 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.